---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-046856"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:00:02.328041+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Absci Q3 revenue $1.7M, net loss $27.4M; achieves AstraZeneca milestone, lowers 2024 cash burn guidance to ~$75M

## Summary
- Revenue $1.7M (up from $0.7M YoY); net loss $27.4M vs $22.0M; cash $127.1M at Sept 30, 2024.
- First milestone achieved under AstraZeneca AI antibody collaboration; entered Twist Bioscience partnership for novel antibody design.
- Gross cash use expected ~$75M for FY2024, below prior guidance of ~$80M; cash runway into first half 2027.
- ABS-101 on track for Phase 1 initiation H1 2025 with interim data H2 2025; ABS-201 candidate selection expected H2 2024.
- R&D expenses $18.0M (up from $11.0M) driven by IND-enabling studies for ABS-101; SG&A $9.3M (down from $9.5M).

## SEC filing metadata
- accession: 0001628280-24-046856
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000162828024046856/0001628280-24-046856-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000162828024046856/absc-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-046856
- JSON: https://secwatch.observer/filing/0001628280-24-046856.json
- Plain text: https://secwatch.observer/filing/0001628280-24-046856.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.